Trial Profile

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Psychiatric disorders
Focus Adverse reactions
Sponsors MycoMedica Life Sciences

Most Recent Events

09 Oct 2024 Status changed from recruiting to completed.
12 Jun 2024 Planned End Date changed from 1 Oct 2024 to 1 Sep 2024.
12 Jun 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com